Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

NCT00663689 | Unknown Phase 2 DMC

• 1 other identifier: cslc0803
• Study Type: interventional
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of erlotinib in patients with asymptomatic brain metastasis advanced NSCLC who was benefitted by first line chemotherapy. Patients with stage IV NSCLC who have one or more asymptomatic brain metastasis who was benefitted by first line chemotherapy will receive oral erlotinib 150mg once daily until disease progression or unacceptable toxicity. These patients' direct DNA sequencing of tumor tissue EGFR exons 18-21 will be analyzed The response was evaluated by RECIST criteria after the patient received erlotinib 6 weeks.If the patients present with progress disease of brain metastasis after the therapy of erlotinib, the patients will receive irradiation of brain metastasis.If the response is stable disease,partial response or complete response,he will be examined by brain MRI every 12 weeks.

Conditions

Non-Small Cell Lung Cancer; Brain Metastases

Keywords

erlotinib

Outcome Measures

Primary Outcomes (1)

• Time of asymptomatic brain metastasis turn into symptomatic brain metastasis

  3/2008~3/2011

Secondary Outcomes (1)

• To determine objective response (CR+PR), time to progression, 6-month survival and 1-year survival,safety.

  3/2008~3/2011

Study Arms (1)

1

EXPERIMENTAL

non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity

Drug: erlotinib

Interventions

erlotinib DRUG

erlotinib 150mg qd until disease progression or unacceptable toxicity.

Also known as: TARVECA

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histological or cytological documented stage IV NSCLC. Sputum cytology alone is excluded
• Extracerebral lesions show stable disease after first line chemotherapy. Patient has recovered from CTCAE grade 3/4 toxicity. Patients who had never received EGFR-TKI or EGFR monoclonal antibody.
• Patients must be at least 18 years.
• ECOG Performance Status 0, 1 or 2.
• Life expectancy of at least 12 weeks.
• Appraisable disease, the presence of at least three lesions if longest diameter \<10 mm by brain MRI.
• Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count (ANC) ³1.5 x 109/L, platelets ³ 100 x 109/L.
• Total bilirubin £ 1.5 x upper limit of normal (ULN)
• ALT and AST \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases.
• Creatinine clearance ³ 60ml/min (calculated according to Cockcroft-gault formula).
• PT-INR/PTT \< 1.2 x ULN.
• Written informed consent.
• Able to comply with study and follow-up procedures.

You may not qualify if:

• Mixed small cell and non-small cell lung cancer histology.
• Any unresolved toxicity\>CTCAE grade 2 from previous anti-cancer therapy.
• Patients with exposure to biotherapy, immunotherapy within 4 weeks of study entry.
• Other concurrent anticancer therapy.
• Patients with exposure to investigational drug therapy outside of this trial.
• Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.
• Any unstable systemic disease (including active infection, hepatic, renal, metabolic disease or seizure disorder requiring medication).
• Significant cardiovascular event: congestive heart failure \>NYHA class 2; unstable angina, active CAD (myocardial infarction more than 1 year prior to study entry is allowed); serious cardiac arrhythmia requiring anti-arrhythmic therapy ( beta blockers or digoxin are permitted) or uncontrolled hypertension.
• Brain metastases or spinal cord compression, if treated before the start of study treatment, and have any symptoms. Symptoms include signs of increased intracranial pressure ,headache,nausea and vomiting,cognitive or affective disturbances,seizures,and focal neurologic symptoms.
• History of another malignancy within the last 5 years except cured carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and superficial bladder tumors \[Ta, Tis \& T1\].
• Pregnant or breast-feeding women.
• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
• Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.

Sponsors & Collaborators

• Guangdong Provincial People's Hospital: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Brain Neoplasms

Interventions

Erlotinib Hydrochloride

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Wu Yilong, MD

  Cancer center of Guangdong PPH

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: April 17, 2008
• First Posted: April 22, 2008
• Study Start: March 1, 2008
• Primary Completion: March 1, 2011
• Study Completion: January 1, 2012
• Last Updated: April 22, 2008

Record last verified: 2008-04